A potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said.
File Image - Close up detail of the bare skin on a man back with scattered moles and freckles. via Getty Images
That combination was compared with Keytruda alone in a mid-stage clinical trial of 157 patients. Patients received either the combination or Keytruda after surgery to remove the tumors.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%A combination of Moderna Inc's melanoma vaccine and Merck & Co's immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.
Consulte Mais informação »
Merck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Consulte Mais informação »
Protecting yourself against COVID-19 during the holidays - New York Amsterdam NewsAs we approach the third anniversary of the beginning of the COVID-19 pandemic, we are faced with COVID fatigue, conflicting information and the false idea that the pandemic is now over. So with the third holiday season of the COVID-19 pandemic in full swing, there are many lingering questions regarding COVID safety. Do I still […]
Consulte Mais informação »
Illinois Coronavirus Updates: COVID Levels Rise in State, Mask RecommendationsHere’s what you need to know about the coronavirus pandemic across Illinois today.
Consulte Mais informação »
Defense of 'China's Fauci' censored by Beijing after zero-COVID reversalZhang Wenhong remains one of the Chinese public's most trusted figures and is key to Beijing's public assurances as the country reopens.
Consulte Mais informação »